Amarin announces new post hoc analysis of aspirin use in REDUCE-IT

Amarin (AMRN) highlighted a new post hoc analysis of aspirin use in REDUCE-IT reinforcing that icosapent ethyl significantly reduced cardiovascular events in high-risk patients. These findings highlight the importance of guideline-directed therapies and further validate the role of icosapent ethyl in comprehensive CV risk management in appropriate patients as studied in REDUCE-IT. This analysis was presented soon after the U.S. Food and Drug Administration, FDA, updated labeling for fenofibrate products that now include language on the neutral PROMINENT trial, reinforcing the lack of CV benefit when fibrates were used alongside statins for cardiovascular risk reduction; a pivotal moment that underscores the need for more effective, evidence-based approaches to residual CV risk.